DocGo (US:DCGO)2026-03-16 22:02Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $74.9 million, down from $120.8 million in Q4 2024, primarily due to the wind-down of migrant-related projects [17] - Adjusted EBITDA for Q4 2025 was a loss of $11.3 million compared to a profit of $1.1 million in Q4 2024 [18] - For the full year 2025, total revenue was $322.2 million, down from $616.6 million in 2024, with an adjusted EBITDA loss of $28.6 million compared to a profit of $60 million in 2024 [18][19] Business Line Data and Key Metrics Changes - Medical transportation services revenue increased to $50.2 million in Q4 2025 from $49.1 million in Q4 2024, driven by growth in both large and small U.S. markets [17][18] - Mobile Health revenue for Q4 2025 was $24.8 million, down from $71.8 million in Q4 2024, but non-migrant Mobile Health revenues increased by 47% [18][19] - SteadyMD generated over $8 million in revenue for the first time in Q4 2025, contributing $6.1 million to DocGo's results [7][8] Market Data and Key Metrics Changes - Medical transportation trips increased by 11%, healthcare in-home visits were up 113%, and telehealth and lab orders were up 50% compared to Q4 2024 [10] - The number of assigned lives in the care gap closure program increased by 12% sequentially, from 1.3 million to over 1.45 million [11] Company Strategy and Development Direction - The company is focused on integrating SteadyMD into its mobile health offerings and aims to consolidate provider networks by the end of Q2 2026 [8] - DocGo is exploring strategic alternatives to maximize shareholder value, engaging an investment bank for this process [15][28] - The company plans to reduce cash outlay in 2026 as early markets mature and become self-sustaining, with a goal of achieving profitability in the second half of 2026 [12][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong demand for services and top-line growth, with an updated revenue guidance for 2026 of $290 million to $310 million [6][25] - The adjusted EBITDA loss is expected to improve to a range of $5 million to $10 million for 2026, down from previous guidance of $15 million to $25 million [26] - Management highlighted the importance of reducing SG&A expenses by 10%-15% through efficiency innovations [32] Other Important Information - The company incurred significant non-cash charges due to the write-down of intangible assets and goodwill, totaling $49.5 million and $22.6 million respectively in Q4 2025 [22] - Cash and cash equivalents at year-end were $68.3 million, down from $95.2 million, primarily due to the acquisition of SteadyMD and delays in collecting migrant-related accounts receivable [23][24] Q&A Session Summary Question: Can you provide details on the strategic alternatives process? - The company has engaged an investment bank to maximize shareholder value but cannot share further details at this time [28][29] Question: What are the drivers behind the increased 2026 guidance? - Increased volumes in Medical Transportation and additional upside from SteadyMD are the primary drivers for the revenue outlook increase [30][31] Question: Can you quantify free cash flow pressures in 2026? - The cash balance at year-end was lower than expected due to delays in collecting $20 million in migrant receivables, but the outlook for collectibility remains unchanged [36][39] Question: What is the status of the payer business and pipeline? - The company continues to see momentum in the payer business, with significant increases in visits and lives referred by payers [45][48] Question: How should we think about EBITDA cadence throughout the year? - Most of the adjusted EBITDA loss is expected in the first half of the year, with a turn to profitability in the second half [70][71]